FDA Approves Pimicotinib for TGCT Following Positive Phase 3 MANEUVER Trial Results
Joe Biden Says Prostate Cancer Is Slowing Him Down Ahead of Memoir Release
Beyond EGFR Mutations: New Study Reveals Why Some Lung Cancer Cells Survive Osimertinib
Kate Middleton Opens Up About Cancer Recovery: Why Healing Is Not Always Linear
Breast Cancer in Michelangelo’s Sistine Chapel? A 500-Year-Old Fresco Sparks a Modern Medical Debate
Preoperative Single-Fraction and Fractionated Stereotactic Radiotherapy Show Comparable Outcomes in Resectable Brain Metastases
We Live in Time: When Cancer Changes the Meaning of Time
Paolo Tarantino: Individualizing T-DXd Treatment Duration in HER2-Positive Breast Cancer
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
